MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.14 1.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.08

Max

1.19

Belangrijke statistieken
By Trading Economics
Inkomsten	15M -38M
Verkoop	-231K 1.6M
EPS	-0.32
Winstmarge	-2,309.454
Werknemers	181
EBITDA	4.3M -38M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+334.82% upside

Dividenden
By Dow Jones
Volgende Winsten	11 aug 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	14M 136M
Vorige openingsprijs	-0.65
Vorige sluitingsprijs	1.14

Nieuwssentiment

By Acuity

84%

16%

361 / 380 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.9101 / 1.14 Steun & Weerstand

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jul 2025, 23:09 UTC

Winsten

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Marktinformatie

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Marktinformatie

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Acquisities, Fusies, Overnames

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Acquisities, Fusies, Overnames

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Winsten

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Marktinformatie

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Marktinformatie

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Acquisities, Fusies, Overnames

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Marktinformatie

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Marktinformatie

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Marktinformatie

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Marktinformatie

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Acquisities, Fusies, Overnames

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Winsten

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Marktinformatie

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Marktinformatie

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Marktinformatie

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Marktinformatie

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

334.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.87 USD 334.82%

Hoogste 12 USD

Laagste 2 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

361 / 380 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.